1 | refractory | 3,544 |
2 | relapsed | 1,222 |
3 | resected | 950 |
4 | disseminated | 806 |
5 | relapsing | 633 |
6 | intractable | 564 |
7 | progressing | 460 |
8 | relapsing-remitting | 370 |
9 | recalcitrant | 197 |
10 | quiescent | 194 |
11 | remitting | 111 |
12 | relapsed/refractory | 81 |
13 | therapy-resistant | 63 |
14 | steroid-dependent | 52 |
15 | metastasized | 46 |
16 | steroid-sensitive | 35 |
17 | steroid-refractory | 29 |
18 | metastasizing | 18 |
19 | aids-associated | 15 |
20 | ige-associated | 15 |
21 | screening-detected | 15 |
22 | therapy-refractory | 14 |
23 | vasopressor-dependent | 11 |
24 | ebv-related | 10 |
25 | -intolerant | 9 |
26 | azi-r | 9 |
27 | cd20-positive | 9 |
28 | erythrodermic | 9 |
29 | corticosteroid-refractory | 8 |
30 | p210 | 8 |
31 | bcr-abl-positive | 7 |
32 | metastasised | 7 |
33 | devonian | 6 |
34 | dextro-transposition | 6 |
35 | myelitis-onset | 6 |
36 | fdg-avid | 5 |
37 | memory-impaired | 5 |
38 | mrd-positive | 5 |
39 | 4.9/1000 | 4 |
40 | absent/hypoplastic | 4 |
41 | advansure | 4 |
42 | cu7 | 4 |
43 | maldi-tof-tof | 4 |
44 | non-refractory | 4 |
45 | paranthropus | 4 |
46 | pediatric-onset | 4 |
47 | secondary-progressive | 4 |
48 | triple-bead | 4 |
49 | unstaged | 4 |
50 | well-delineated | 4 |
51 | ylidenemalononitriles | 4 |
52 | advanced-pd | 3 |
53 | chronic-active | 3 |
54 | hard-sphere | 3 |
55 | non-hbv | 3 |
56 | posture-responsive | 3 |
57 | remitting-relapsing | 3 |
58 | stage-ib | 3 |
59 | summer-type | 3 |
60 | vaccine-primed | 3 |
61 | 1.0/100 | 2 |
62 | 1.8±0.8 | 2 |
63 | anti-disseminated | 2 |
64 | autogen | 2 |
65 | catecholamine-refractory | 2 |
66 | dimethylhydrazine | 2 |
67 | egcg-supplemented | 2 |
68 | leucopenic | 2 |
69 | low-phenolic | 2 |
70 | naїve | 2 |
71 | polyostotic | 2 |
72 | primary-progressive | 2 |
73 | proctitis-type | 2 |
74 | random-motion | 2 |
75 | receptor-unknown | 2 |
76 | relapsing–remitting | 2 |
77 | rhmpo-induced | 2 |
78 | streptocephalus | 2 |
79 | three-time-point | 2 |
80 | vam-b-treated | 2 |
81 | zen-induced | 2 |
82 | -24.08 | 1 |
83 | -remitting | 1 |
84 | 0.792-30 | 1 |
85 | 1.64-7.99 | 1 |
86 | 10.1+/-1.5* | 1 |
87 | 10.5/1000 | 1 |
88 | 1026±4 | 1 |
89 | 115+/-48 | 1 |
90 | 1175.9-1361.2 | 1 |
91 | 120±16 | 1 |
92 | 122.4±6.0° | 1 |
93 | 139,800 | 1 |
94 | 14.00-16.50 | 1 |
95 | 17.7+/-8.6 | 1 |
96 | 19-d-old | 1 |
97 | 1900-2500 | 1 |
98 | 196/282 | 1 |
99 | 2.52-21.18 | 1 |
100 | 2.5±0.75 | 1 |
101 | 20.3+/-8.1 | 1 |
102 | 20.8±0.3 | 1 |
103 | 20–80 | 1 |
104 | 240/27/3000 | 1 |
105 | 26.0±2.9-28.9±1.7 | 1 |
106 | 27,851 | 1 |
107 | 274.47 | 1 |
108 | 29,997 | 1 |
109 | 29-334 | 1 |
110 | 2d-hetereonuclear | 1 |
111 | 3,500-4,000 | 1 |
112 | 3,509 | 1 |
113 | 304.5 | 1 |
114 | 33.27±24.15 | 1 |
115 | 368+/-30 | 1 |
116 | 38+/-12 | 1 |
117 | 39.679 | 1 |
118 | 4,904 | 1 |
119 | 470-500 | 1 |
120 | 5,967 | 1 |
121 | 508-521 | 1 |
122 | 520.27 | 1 |
123 | 6-oxo-prostaglandin | 1 |
124 | 6.12-6.54 | 1 |
125 | 6.169 | 1 |
126 | 616.3 | 1 |
127 | 64.3+/-10.4* | 1 |
128 | 795.6 | 1 |
129 | 796.3 | 1 |
130 | 8.02-8.82 | 1 |
131 | 800mm | 1 |
132 | 81-patient | 1 |
133 | 86.5-93.4 | 1 |
134 | 92+/-33 | 1 |
135 | 96±3 | 1 |
136 | 970-1352 | 1 |
137 | ac-related | 1 |
138 | acne+ | 1 |
139 | actinide-ligand | 1 |
140 | acunav | 1 |
141 | adv13.1 | 1 |
142 | aeroxide | 1 |
143 | anti-tnfα-naïve | 1 |
144 | antroponotic | 1 |
145 | arfomoterol | 1 |
146 | assumably | 1 |
147 | bp-3-bearing | 1 |
148 | buccal/labial | 1 |
149 | butanol-hcl | 1 |
150 | butwal | 1 |
151 | cmv-ie-driven | 1 |
152 | coated/bonded | 1 |
153 | copsoq-data | 1 |
154 | cpg-motif | 1 |
155 | ctd/ssc | 1 |
156 | cyclophosphamide-associated | 1 |
157 | dialysisdependent | 1 |
158 | discussed.although | 1 |
159 | dyshormonal | 1 |
160 | endoscopically-placed | 1 |
161 | enhancement≥50 | 1 |
162 | fractory | 1 |
163 | fura2-loaded | 1 |
164 | group:577 | 1 |
165 | group=61.79+/-15.18 | 1 |
166 | hfwco | 1 |
167 | hostacerin | 1 |
168 | hv-like | 1 |
169 | hydrosilane | 1 |
170 | hypertensives.in | 1 |
171 | iga-kappa | 1 |
172 | inas-based | 1 |
173 | infranodal | 1 |
174 | jfe-treated | 1 |
175 | kms4034-treated | 1 |
176 | kttv | 1 |
177 | liver-based | 1 |
178 | low-tumor-burden | 1 |
179 | lps/pepg-induced | 1 |
180 | medium-dose-rate | 1 |
181 | mesangio-proliferative | 1 |
182 | met793 | 1 |
183 | methylene-substituted | 1 |
184 | microlinear | 1 |
185 | mpa-r. | 1 |
186 | ms/427.3 | 1 |
187 | murchison | 1 |
188 | non-monochorionic | 1 |
189 | ofcurrent | 1 |
190 | ofpregnancy | 1 |
191 | pb-responsive | 1 |
192 | plagiarised | 1 |
193 | pp/tp | 1 |
194 | progressive/relapsing-remitting | 1 |
195 | pr≥200 | 1 |
196 | relaping | 1 |
197 | relapsing-progressive | 1 |
198 | s1and | 1 |
199 | sb203080 | 1 |
200 | serological/mucosal | 1 |
201 | sms-kcnr | 1 |
202 | stable/ | 1 |
203 | te-e'≥38 | 1 |
204 | tracheostomy-to-first | 1 |
205 | transcaval | 1 |
206 | under-training | 1 |
207 | uplc-orbitrap | 1 |
208 | vasopressor-dependency | 1 |
209 | ±100.8 | 1 |
210 | ±119.3 | 1 |
211 | β-cell-specific | 1 |
212 | δep/gfr | 1 |
213 | ∼170 | 1 |
214 | ∼60-70 | 1 |
215 | ≥8.3 | 1 |
1 | -24.08 | 1 |
2 | -intolerant | 9 |
3 | -remitting | 1 |
4 | 0.792-30 | 1 |
5 | 1.0/100 | 2 |
6 | 1.64-7.99 | 1 |
7 | 1.8±0.8 | 2 |
8 | 10.1+/-1.5* | 1 |
9 | 10.5/1000 | 1 |
10 | 1026±4 | 1 |
11 | 115+/-48 | 1 |
12 | 1175.9-1361.2 | 1 |
13 | 120±16 | 1 |
14 | 122.4±6.0° | 1 |
15 | 139,800 | 1 |
16 | 14.00-16.50 | 1 |
17 | 17.7+/-8.6 | 1 |
18 | 19-d-old | 1 |
19 | 1900-2500 | 1 |
20 | 196/282 | 1 |
21 | 2.52-21.18 | 1 |
22 | 2.5±0.75 | 1 |
23 | 20.3+/-8.1 | 1 |
24 | 20.8±0.3 | 1 |
25 | 20–80 | 1 |
26 | 240/27/3000 | 1 |
27 | 26.0±2.9-28.9±1.7 | 1 |
28 | 27,851 | 1 |
29 | 274.47 | 1 |
30 | 29,997 | 1 |
31 | 29-334 | 1 |
32 | 2d-hetereonuclear | 1 |
33 | 3,500-4,000 | 1 |
34 | 3,509 | 1 |
35 | 304.5 | 1 |
36 | 33.27±24.15 | 1 |
37 | 368+/-30 | 1 |
38 | 38+/-12 | 1 |
39 | 39.679 | 1 |
40 | 4,904 | 1 |
41 | 4.9/1000 | 4 |
42 | 470-500 | 1 |
43 | 5,967 | 1 |
44 | 508-521 | 1 |
45 | 520.27 | 1 |
46 | 6-oxo-prostaglandin | 1 |
47 | 6.12-6.54 | 1 |
48 | 6.169 | 1 |
49 | 616.3 | 1 |
50 | 64.3+/-10.4* | 1 |
51 | 795.6 | 1 |
52 | 796.3 | 1 |
53 | 8.02-8.82 | 1 |
54 | 800mm | 1 |
55 | 81-patient | 1 |
56 | 86.5-93.4 | 1 |
57 | 92+/-33 | 1 |
58 | 96±3 | 1 |
59 | 970-1352 | 1 |
60 | absent/hypoplastic | 4 |
61 | ac-related | 1 |
62 | acne+ | 1 |
63 | actinide-ligand | 1 |
64 | acunav | 1 |
65 | adv13.1 | 1 |
66 | advanced-pd | 3 |
67 | advansure | 4 |
68 | aeroxide | 1 |
69 | aids-associated | 15 |
70 | anti-disseminated | 2 |
71 | anti-tnfα-naïve | 1 |
72 | antroponotic | 1 |
73 | arfomoterol | 1 |
74 | assumably | 1 |
75 | autogen | 2 |
76 | azi-r | 9 |
77 | bcr-abl-positive | 7 |
78 | bp-3-bearing | 1 |
79 | buccal/labial | 1 |
80 | butanol-hcl | 1 |
81 | butwal | 1 |
82 | catecholamine-refractory | 2 |
83 | cd20-positive | 9 |
84 | chronic-active | 3 |
85 | cmv-ie-driven | 1 |
86 | coated/bonded | 1 |
87 | copsoq-data | 1 |
88 | corticosteroid-refractory | 8 |
89 | cpg-motif | 1 |
90 | ctd/ssc | 1 |
91 | cu7 | 4 |
92 | cyclophosphamide-associated | 1 |
93 | devonian | 6 |
94 | dextro-transposition | 6 |
95 | dialysisdependent | 1 |
96 | dimethylhydrazine | 2 |
97 | discussed.although | 1 |
98 | disseminated | 806 |
99 | dyshormonal | 1 |
100 | ebv-related | 10 |
101 | egcg-supplemented | 2 |
102 | endoscopically-placed | 1 |
103 | enhancement≥50 | 1 |
104 | erythrodermic | 9 |
105 | fdg-avid | 5 |
106 | fractory | 1 |
107 | fura2-loaded | 1 |
108 | group:577 | 1 |
109 | group=61.79+/-15.18 | 1 |
110 | hard-sphere | 3 |
111 | hfwco | 1 |
112 | hostacerin | 1 |
113 | hv-like | 1 |
114 | hydrosilane | 1 |
115 | hypertensives.in | 1 |
116 | iga-kappa | 1 |
117 | ige-associated | 15 |
118 | inas-based | 1 |
119 | infranodal | 1 |
120 | intractable | 564 |
121 | jfe-treated | 1 |
122 | kms4034-treated | 1 |
123 | kttv | 1 |
124 | leucopenic | 2 |
125 | liver-based | 1 |
126 | low-phenolic | 2 |
127 | low-tumor-burden | 1 |
128 | lps/pepg-induced | 1 |
129 | maldi-tof-tof | 4 |
130 | medium-dose-rate | 1 |
131 | memory-impaired | 5 |
132 | mesangio-proliferative | 1 |
133 | met793 | 1 |
134 | metastasised | 7 |
135 | metastasized | 46 |
136 | metastasizing | 18 |
137 | methylene-substituted | 1 |
138 | microlinear | 1 |
139 | mpa-r. | 1 |
140 | mrd-positive | 5 |
141 | ms/427.3 | 1 |
142 | murchison | 1 |
143 | myelitis-onset | 6 |
144 | naїve | 2 |
145 | non-hbv | 3 |
146 | non-monochorionic | 1 |
147 | non-refractory | 4 |
148 | ofcurrent | 1 |
149 | ofpregnancy | 1 |
150 | p210 | 8 |
151 | paranthropus | 4 |
152 | pb-responsive | 1 |
153 | pediatric-onset | 4 |
154 | plagiarised | 1 |
155 | polyostotic | 2 |
156 | posture-responsive | 3 |
157 | pp/tp | 1 |
158 | primary-progressive | 2 |
159 | proctitis-type | 2 |
160 | progressing | 460 |
161 | progressive/relapsing-remitting | 1 |
162 | pr≥200 | 1 |
163 | quiescent | 194 |
164 | random-motion | 2 |
165 | recalcitrant | 197 |
166 | receptor-unknown | 2 |
167 | refractory | 3,544 |
168 | relaping | 1 |
169 | relapsed | 1,222 |
170 | relapsed/refractory | 81 |
171 | relapsing | 633 |
172 | relapsing-progressive | 1 |
173 | relapsing-remitting | 370 |
174 | relapsing–remitting | 2 |
175 | remitting | 111 |
176 | remitting-relapsing | 3 |
177 | resected | 950 |
178 | rhmpo-induced | 2 |
179 | s1and | 1 |
180 | sb203080 | 1 |
181 | screening-detected | 15 |
182 | secondary-progressive | 4 |
183 | serological/mucosal | 1 |
184 | sms-kcnr | 1 |
185 | stable/ | 1 |
186 | stage-ib | 3 |
187 | steroid-dependent | 52 |
188 | steroid-refractory | 29 |
189 | steroid-sensitive | 35 |
190 | streptocephalus | 2 |
191 | summer-type | 3 |
192 | te-e'≥38 | 1 |
193 | therapy-refractory | 14 |
194 | therapy-resistant | 63 |
195 | three-time-point | 2 |
196 | tracheostomy-to-first | 1 |
197 | transcaval | 1 |
198 | triple-bead | 4 |
199 | under-training | 1 |
200 | unstaged | 4 |
201 | uplc-orbitrap | 1 |
202 | vaccine-primed | 3 |
203 | vam-b-treated | 2 |
204 | vasopressor-dependency | 1 |
205 | vasopressor-dependent | 11 |
206 | well-delineated | 4 |
207 | ylidenemalononitriles | 4 |
208 | zen-induced | 2 |
209 | ±100.8 | 1 |
210 | ±119.3 | 1 |
211 | β-cell-specific | 1 |
212 | δep/gfr | 1 |
213 | ∼170 | 1 |
214 | ∼60-70 | 1 |
215 | ≥8.3 | 1 |
1 | 64.3+/-10.4* | 1 |
2 | 10.1+/-1.5* | 1 |
3 | acne+ | 1 |
4 | mpa-r. | 1 |
5 | stable/ | 1 |
6 | 3,500-4,000 | 1 |
7 | 10.5/1000 | 1 |
8 | 4.9/1000 | 4 |
9 | 240/27/3000 | 1 |
10 | 1.0/100 | 2 |
11 | pr≥200 | 1 |
12 | 470-500 | 1 |
13 | 1900-2500 | 1 |
14 | 139,800 | 1 |
15 | p210 | 8 |
16 | 368+/-30 | 1 |
17 | 0.792-30 | 1 |
18 | 14.00-16.50 | 1 |
19 | enhancement≥50 | 1 |
20 | ∼60-70 | 1 |
21 | ∼170 | 1 |
22 | sb203080 | 1 |
23 | 20–80 | 1 |
24 | adv13.1 | 1 |
25 | 20.3+/-8.1 | 1 |
26 | 508-521 | 1 |
27 | 27,851 | 1 |
28 | 1175.9-1361.2 | 1 |
29 | 38+/-12 | 1 |
30 | 970-1352 | 1 |
31 | 8.02-8.82 | 1 |
32 | 196/282 | 1 |
33 | 20.8±0.3 | 1 |
34 | 616.3 | 1 |
35 | 796.3 | 1 |
36 | ms/427.3 | 1 |
37 | ≥8.3 | 1 |
38 | ±119.3 | 1 |
39 | 92+/-33 | 1 |
40 | met793 | 1 |
41 | 96±3 | 1 |
42 | 86.5-93.4 | 1 |
43 | 4,904 | 1 |
44 | 29-334 | 1 |
45 | 6.12-6.54 | 1 |
46 | 1026±4 | 1 |
47 | 304.5 | 1 |
48 | 33.27±24.15 | 1 |
49 | 2.5±0.75 | 1 |
50 | 795.6 | 1 |
51 | 17.7+/-8.6 | 1 |
52 | 120±16 | 1 |
53 | 26.0±2.9-28.9±1.7 | 1 |
54 | 520.27 | 1 |
55 | 274.47 | 1 |
56 | 5,967 | 1 |
57 | group:577 | 1 |
58 | 29,997 | 1 |
59 | cu7 | 4 |
60 | ±100.8 | 1 |
61 | 1.8±0.8 | 2 |
62 | -24.08 | 1 |
63 | 2.52-21.18 | 1 |
64 | group=61.79+/-15.18 | 1 |
65 | te-e'≥38 | 1 |
66 | 115+/-48 | 1 |
67 | 3,509 | 1 |
68 | 6.169 | 1 |
69 | 39.679 | 1 |
70 | 1.64-7.99 | 1 |
71 | iga-kappa | 1 |
72 | copsoq-data | 1 |
73 | stage-ib | 3 |
74 | β-cell-specific | 1 |
75 | low-phenolic | 2 |
76 | erythrodermic | 9 |
77 | leucopenic | 2 |
78 | non-monochorionic | 1 |
79 | antroponotic | 1 |
80 | polyostotic | 2 |
81 | absent/hypoplastic | 4 |
82 | ctd/ssc | 1 |
83 | triple-bead | 4 |
84 | endoscopically-placed | 1 |
85 | lps/pepg-induced | 1 |
86 | zen-induced | 2 |
87 | rhmpo-induced | 2 |
88 | fura2-loaded | 1 |
89 | coated/bonded | 1 |
90 | unstaged | 4 |
91 | vaccine-primed | 3 |
92 | memory-impaired | 5 |
93 | liver-based | 1 |
94 | inas-based | 1 |
95 | plagiarised | 1 |
96 | metastasised | 7 |
97 | relapsed | 1,222 |
98 | well-delineated | 4 |
99 | kms4034-treated | 1 |
100 | vam-b-treated | 2 |
101 | jfe-treated | 1 |
102 | cyclophosphamide-associated | 1 |
103 | ige-associated | 15 |
104 | aids-associated | 15 |
105 | ac-related | 1 |
106 | ebv-related | 10 |
107 | disseminated | 806 |
108 | anti-disseminated | 2 |
109 | resected | 950 |
110 | screening-detected | 15 |
111 | egcg-supplemented | 2 |
112 | methylene-substituted | 1 |
113 | metastasized | 46 |
114 | fdg-avid | 5 |
115 | 19-d-old | 1 |
116 | s1and | 1 |
117 | actinide-ligand | 1 |
118 | advanced-pd | 3 |
119 | aeroxide | 1 |
120 | hv-like | 1 |
121 | intractable | 564 |
122 | hydrosilane | 1 |
123 | dimethylhydrazine | 2 |
124 | summer-type | 3 |
125 | proctitis-type | 2 |
126 | hard-sphere | 3 |
127 | advansure | 4 |
128 | medium-dose-rate | 1 |
129 | pb-responsive | 1 |
130 | posture-responsive | 3 |
131 | relapsing-progressive | 1 |
132 | secondary-progressive | 4 |
133 | primary-progressive | 2 |
134 | mesangio-proliferative | 1 |
135 | chronic-active | 3 |
136 | steroid-sensitive | 35 |
137 | cd20-positive | 9 |
138 | mrd-positive | 5 |
139 | bcr-abl-positive | 7 |
140 | naїve | 2 |
141 | anti-tnfα-naïve | 1 |
142 | cpg-motif | 1 |
143 | maldi-tof-tof | 4 |
144 | under-training | 1 |
145 | relaping | 1 |
146 | bp-3-bearing | 1 |
147 | relapsing | 633 |
148 | remitting-relapsing | 3 |
149 | progressing | 460 |
150 | remitting | 111 |
151 | -remitting | 1 |
152 | relapsing-remitting | 370 |
153 | progressive/relapsing-remitting | 1 |
154 | relapsing–remitting | 2 |
155 | metastasizing | 18 |
156 | discussed.although | 1 |
157 | infranodal | 1 |
158 | buccal/labial | 1 |
159 | dyshormonal | 1 |
160 | serological/mucosal | 1 |
161 | transcaval | 1 |
162 | butwal | 1 |
163 | butanol-hcl | 1 |
164 | arfomoterol | 1 |
165 | 800mm | 1 |
166 | devonian | 6 |
167 | low-tumor-burden | 1 |
168 | autogen | 2 |
169 | cmv-ie-driven | 1 |
170 | hypertensives.in | 1 |
171 | 6-oxo-prostaglandin | 1 |
172 | hostacerin | 1 |
173 | dextro-transposition | 6 |
174 | random-motion | 2 |
175 | murchison | 1 |
176 | receptor-unknown | 2 |
177 | hfwco | 1 |
178 | uplc-orbitrap | 1 |
179 | pp/tp | 1 |
180 | azi-r | 9 |
181 | 2d-hetereonuclear | 1 |
182 | microlinear | 1 |
183 | δep/gfr | 1 |
184 | sms-kcnr | 1 |
185 | ylidenemalononitriles | 4 |
186 | streptocephalus | 2 |
187 | paranthropus | 4 |
188 | pediatric-onset | 4 |
189 | myelitis-onset | 6 |
190 | -intolerant | 9 |
191 | recalcitrant | 197 |
192 | therapy-resistant | 63 |
193 | quiescent | 194 |
194 | steroid-dependent | 52 |
195 | vasopressor-dependent | 11 |
196 | dialysisdependent | 1 |
197 | 81-patient | 1 |
198 | ofcurrent | 1 |
199 | three-time-point | 2 |
200 | tracheostomy-to-first | 1 |
201 | acunav | 1 |
202 | non-hbv | 3 |
203 | kttv | 1 |
204 | ofpregnancy | 1 |
205 | vasopressor-dependency | 1 |
206 | assumably | 1 |
207 | fractory | 1 |
208 | refractory | 3,544 |
209 | steroid-refractory | 29 |
210 | corticosteroid-refractory | 8 |
211 | catecholamine-refractory | 2 |
212 | non-refractory | 4 |
213 | therapy-refractory | 14 |
214 | relapsed/refractory | 81 |
215 | 122.4±6.0° | 1 |